Table 2.
Characteristics of study patients with and without BTA use in 2012
| Characteristic | Medicare
|
Commercial
|
||
|---|---|---|---|---|
| BTA use (N=5,154) | No BTA use (N=5,818) | BTA use (N=8,719) | No BTA use (N=11,446) | |
| Agent used | ||||
| Zoledronic acid | 49% | 56% | ||
| Pamidronate | 5% | 4% | ||
| Denosumab | 52% | 47% | ||
| Multiple agents | 6% | 7% | ||
| Mean age (SD) in study year | 72.9 (10.3) | 73.0 (10.5) | 60.4 (11.1) | 59.4 (14.0) |
| Percentage of female | 53% | 43% | 53% | 43% |
| Tumor type | ||||
| Breast | 44% | 19% | 46% | 26% |
| Prostate | 34% | 28% | 23% | 17% |
| Lung | 16% | 34% | 21% | 32% |
| Other | 6% | 19% | 9% | 26% |
| Year of bone metastasis diagnosis | ||||
| 2012 | 43% | 66% | 42% | 65% |
| 2011 | 22% | 16% | 28% | 18% |
| 2010 or earlier | 35% | 18% | 30% | 17% |
| Mean (SD) Charlson comorbidity index score (in study year) | 1.8 (2.0) | 2.4 (2.3) | 1.2 (1.6) | 1.6 (1.7) |
| Mean (SD) Charlson comorbidity index score in 2011–2012 | n=2,799 2.3 (2.3) |
n=1,700 2.9 (2.5) |
n=4,440 1.5 (1.9) |
n=3,368 1.9 (2.1) |
| Prior BTA use | ||||
| 2011 | n=2,799 76% |
n=1,700 18% |
n=4,440 72% |
n=3,368 19% |
| 2010 | n=1,684 80% |
n=860 27% |
n=2,013 78% |
n=1,348 29% |
| 2009 | n=1,024 77% |
n=530 29% |
n=1,050 78% |
n=752 39% |
Abbreviations: BTA, bone-targeting agent; SD, standard deviation.